Journal
EBIOMEDICINE
Volume 28, Issue -, Pages 43-50Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2018.01.044
Keywords
Urothelial cancer; Molecular theranostics; Imaging theranostics; Omics; Precision medicine
Funding
- European Commission [GEN2PHEN FP7-200754, RD-Connect FP7-305444, UPGx H2020-668353]
Ask authors/readers for more resources
Unmet needs in urothelial cancer management represent an important challenge in our effort to improve long-term overall and disease-free survival rates with no significant compromise in quality of life. Radical cystectomy with pelvic lymph node dissection is the standard for the management of muscle-invasive, non-metastatic cancers. In spite of a 90% local disease control, up to 50% of patients ultimately die of distant metastasis. Bladder preservation using chemo-radiation is an acceptable alternative, but optimal patient selection remains elusive. Recent research is focused on the employment of tailored-made strategies in urothelial cancer exploiting the potential of theranostics in patient selection for specific therapies. Herein, we review the current knowledge on molecular theranostics in urothelial cancer and we suggest that this is the time to move toward imaging theranostics, if tailored-made disease management and patient stratification is envisaged. (c) 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available